The effect of Nanocurcumin on liver fibrosis

INTERVENTION: Intervention 1: Intervention group:Nanocurcumin 40 mg Exir Nano Sina (twice a day),The patients will be received 1 capsule of 40 mg of nano curcumin two times daily for 4 months. Intervention 2: Control group: Placebo (twice a day), The patients will be received 1 capsule of an identical‐looking placebo two times daily for 4 months (Appearance similarity of both supplement and placebo in terms of shape and color). CONDITION: Liver fibrosis. PRIMARY OUTCOME: Liver fibrosis. Timepoint: Before and 16 weekes after the intervention. Method of measurement: Determining the amount of liver tissue fibrosis by using Elastography (2D Shear Wave Elastography‐ SWE). Liver steatosis. Timepoint: Before and 16 weekes after the intervention. Method of measurement: Determining the amount of liver tissue steatosis by using Elastography (2D Shear Wave Elastography‐ SWE). SECONDARY OUTCOME: Anthropometric indicators (fat mass and fat‐free mass). Timepoint: Baseline and 16 weeks. Method of measurement: Using the body composition device. Anthropometric indicators (waist circumference). Timepoint: Baseline and 16 weeks. Method of measurement: Waist size in the distance between the hip bone and the last rib (cm). Anthropometric indicators (weight). Timepoint: Baseline and 16 weeks. Method of measurement: Weight of a person with light clothes and without shoes (Kg). Anthropometric indices (body mass index). Timepoint: Baseline and 16 weeks. Method of measurement: The ratio of weight (in kilograms) to the square of height (in meters). Blood pressure. Timepoint: Baseline and 16 weeks. Method of measurement: Measurement of systolic and diastolic blood pressure (mm Hg). Fasting glucose, serum insulin. Timepoint: Baseline and 16 weeks. Method of measurement: lab kit. Inflammatory factors Hs‐CRP and ESR. Timepoint: Baseline and 16 weeks. Method of measurement: lab kit. Lipid profile (HDL‐c, LDL‐c, TG, TC). Timepoint: Baseline and 16 weeks. Method of measurement: lab kit. Liver function tests (LDH ?ALT?AST?Albumin ?GGT ?ALP?Bilirubin Total and Bilirubin Direct). Timepoint: Baseline and 16 weeks. Method of measurement: lab kit. INCLUSION CRITERIA: patients between 30 and 70 years of age with liver fibrosis F=2 referring to the liver and digestive consultation and treatment clinic